People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Information About Us Contact us Feedback Terms Of Service Privacy Policy Subscriber Agreement JPost Jobs Cancel Subscription Sitemap Customer Service JP Store ...

Novo Nordisk announced its decision to partner with digital health providers to streamline access to Wegovy after a U.S. shortage has eased. And Novo will offer direct-to-consumer access via its ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...